MediSix Therapeutics is a preclinical immune cell engineering company dedicated to developing novel CAR T cell therapies for T cell malignancies, solid tumours, and autoimmune diseases. At MediSix, our Mission is to develop effective T cell therapies by leveraging an array of proprietary technologies that improve and expand T cell function. Our technology platforms originate from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. MediSix is using these ground-breaking technologies to develop T cell therapies against challenging indications with great unmet clinical need. For more information, please visit https://medisixtx.com/.MediSix Therapeutics is headquartered in Singapore with discovery research laboratories located in Biopolis.MediSix Therapeutics is committed to providing equal employment opportunities and a safe work environment free of harassment.
MediSix Therapeutics is a preclinical immune cell engineering company dedicated to developing novel CAR T cell therapies for T cell malignancies, solid tumours, and autoimmune diseases. At MediSix, our Mission is to develop effective T cell therapies by leveraging an array of proprietary technologies that improve and expand T cell function. Our technology platforms originate from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. MediSix is using these ground-breaking technologies to develop T cell therapies against challenging indications with great unmet clinical need. For more information, please visit https://medisixtx.com/.MediSix Therapeutics is headquartered in Singapore with discovery research laboratories located in Biopolis.MediSix Therapeutics is committed to providing equal employment opportunities and a safe work environment free of harassment.
MediSix Therapeutics is a preclinical immune cell engineering company dedicated to developing novel CAR T cell therapies for T cell malignancies, solid tumours, and autoimmune diseases. At MediSix, our Mission is to develop effective T cell therapies by leveraging an array of proprietary technologies that improve and expand T cell function. Our technology platforms originate from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. MediSix is using these ground-breaking technologies to develop T cell therapies against challenging indications with great unmet clinical need. For more information, please visit https://medisixtx.com/.MediSix Therapeutics is headquartered in Singapore with discovery research laboratories located in Biopolis.MediSix Therapeutics is committed to providing equal employment opportunities and a safe work environment free of harassment.